95 related articles for article (PubMed ID: 10822991)
21. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
22. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
23. Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications.
Sillaber C; Mayerhofer M; Aichberger KJ; Krauth MT; Valent P
Eur J Clin Invest; 2004 Aug; 34 Suppl 2():2-11. PubMed ID: 15291801
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
25. [Relationship between blast crisis of chronic myeloid leukemias and abnormality of p16 and calcitonin genes].
Xu D; Hong W; Wang S
Zhonghua Zhong Liu Za Zhi; 2000 Mar; 22(2):151-3. PubMed ID: 11776646
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
Agirre X; Román-Gómez J; Vázquez I; Jiménez-Velasco A; Larráyoz MJ; Lahortiga I; Andreu EJ; Márquez J; Beltrán de Heredia JM; Odero MD; Prósper F; Calasanz MJ
Cancer Genet Cytogenet; 2005 Jul; 160(1):22-6. PubMed ID: 15949566
[TBL] [Abstract][Full Text] [Related]
27. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia.
Van Limbergen H; Beverloo HB; van Drunen E; Janssens A; Hählen K; Poppe B; Van Roy N; Marynen P; De Paepe A; Slater R; Speleman F
Genes Chromosomes Cancer; 2001 Mar; 30(3):274-82. PubMed ID: 11170285
[TBL] [Abstract][Full Text] [Related]
28. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
[TBL] [Abstract][Full Text] [Related]
29. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
30. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
31. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
32. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
33. [Study of calcitonin gene methylation in chronic myeloid leukemia by using Hpa II-PCR].
Tan B; Cao P; Qi Z
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):371-3. PubMed ID: 12080652
[TBL] [Abstract][Full Text] [Related]
34. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.
Issa JP; Kantarjian H; Mohan A; O'Brien S; Cortes J; Pierce S; Talpaz M
Blood; 1999 Mar; 93(6):2075-80. PubMed ID: 10068681
[TBL] [Abstract][Full Text] [Related]
35. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Barnes DJ; Schultheis B; Adedeji S; Melo JV
Oncogene; 2005 Sep; 24(42):6432-40. PubMed ID: 16007188
[TBL] [Abstract][Full Text] [Related]
37. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression.
Brazma D; Grace C; Howard J; Melo JV; Holyoke T; Apperley JF; Nacheva EP
Genes Chromosomes Cancer; 2007 Nov; 46(11):1039-50. PubMed ID: 17696194
[TBL] [Abstract][Full Text] [Related]
38. Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia.
La Starza R; Testoni N; Lafage-Pochitaloff M; Ruggeri D; Ottaviani E; Perla G; Martelli MF; Marynen P; Mecucci C
Haematologica; 2002 Feb; 87(2):143-7. PubMed ID: 11836164
[TBL] [Abstract][Full Text] [Related]
39. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
[TBL] [Abstract][Full Text] [Related]
40. Linking miRNA regulation to BCR-ABL expression: the next dimension.
Faber J; Gregory RI; Armstrong SA
Cancer Cell; 2008 Jun; 13(6):467-9. PubMed ID: 18538729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
